cilgavimab/tixagevimab (Evusheld, AZD7442)
Jump to navigation
Jump to search
Indications
- combination used for pre-exposure prevention of Covid-19
* reduces symptomatic Covid-19 by 83%[3]
Dosage
- two gluteal 300 mg (3 mL) intramuscular injections of cilgavimab & tixagevimab
* cilgavimab 150 mg/1.5 mL (100 mg/mL) in a single-dose vial
* tixagevimab 150 mg/1.5 mL (100 mg/mL) in a single-dose vial
* one hour observation period after injections
* a negative SARS-CoV2 RNA test 5 days prior to administration
* at least 2 weeks after Covid-19 vaccine
Adverse effects
- fatigue
- edema
- headache
- cough
- potentially serious:
- chest pain
- pain or discomfort in one or both arms, the back, neck, jaw or stomach
- dyspnea
- cold sweat
- nausea
- lightheadedness
Mechanism of action
- combination of monoclonal antibodies specifically directed against the spike protein of SARS-CoV2
More general terms
References
- ↑ MedlinePlus: Tixagevimab and Cilgavimab https://medlineplus.gov/druginfo/meds/a621058.html
- ↑ Berg S 3 tips for doctors on using Evusheld for COVID-19 protection. AMA Public Health. April 14, 2022 https://www.ama-assn.org/delivering-care/public-health/3-tips-doctors-using-evusheld-covid-19-protection
- ↑ 3.0 3.1 Levin MJ et al. Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19. N Engl J Med 2022 Apr 20; [e-pub]. https://www.nejm.org/doi/10.1056/NEJMoa2116620
- ↑ HIGHLIGHTS OF EMERGENCY USE AUTHORIZATION (EUA) Evusheld (tixagevimab) injection; (cilgavimab) injection, co-packaged for intramuscular use. https://www.fda.gov/media/154701/download